Lexagene Holdings Inc. (V:LXG)
Business Focus: N/A
Feb 24, 2023 07:45 pm ET
TSX Venture Exchange Stock Maintenance Bulletins
VANCOUVER, BC, Feb. 24, 2023 /CNW/ -
Feb 24, 2023 08:45 am ET
LexaGene Files for Chapter 7 Bankruptcy
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), announces that it has ceased operations, laid off its staff, and, together with its direct subsidiary LexaGene, Inc., and its indirect subsidiary Bionomics...
Feb 21, 2023 03:45 pm ET
IIROC Trading Halt - LXG
VANCOUVER, BC, Feb. 21, 2023 /CNW/ - The following issues have been halted by IIROC:
Feb 10, 2023 02:17 pm ET
LexaGene Holdings Announces Results of February 8, 2023 Annual General Meeting
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the MiQLab™ System for automated multiplex PCR testing, announces the results of its annual general meeting...
Feb 08, 2023 08:00 am ET
LexaGene Provides Update on BioPharma Sector
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the MiQLab™ System for automated, genetic testing, is pleased to provide the following update on...
Jan 18, 2023 08:00 am ET
LexaGene’s MiQLab System Detects Mycoplasma at Minute Levels, Rousing Additional Interest from BioPharma Customers
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the MiQLabTM System for automated, genetic testing, is pleased to announce exciting news...
Dec 16, 2022 08:00 am ET
BioPharma Engages LexaGene in Second Feasibility Study
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the MiQLab® System for automated, genetic testing, is pleased to announce the large biopharma...
Dec 07, 2022 08:00 am ET
LexaGene Holdings Proposes to Amend Warrants Terms
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the MiQLab® System for automated, genetic testing, announces that it intends to amend the...
Nov 22, 2022 08:00 am ET
LexaGene Successfully Completes Statement of Work for BioPharma Company
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the MiQLab® System for automated, genetic testing, is pleased to announce the completion of a...
Nov 01, 2022 04:01 pm ET
LexaGene Closes Secured Convertible Note Transaction
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the MiQLab® System for automated multiplex PCR testing, announces that it has issued a 12% secured...
Oct 27, 2022 05:18 pm ET
LexaGene Holdings Proposes to Amend Warrants Terms
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the MiQLab® System for automated multiplex PCR testing, announces that it intends to amend the exercise price...
Oct 24, 2022 08:00 am ET
LexaGene Enters into Secured Convertible Note Agreement
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the MiQLab® System for automated multiplex PCR testing, announces that it has entered into a secured...
Oct 20, 2022 07:45 am ET
Large Biopharma Company Engages LexaGene in Statement of Work to Expedite Technology Validation
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the MiQLab® System for automated, genetic testing, is pleased to announce that it has signed a...
Oct 13, 2022 07:45 am ET
LexaGene Receives Signed Quote from Large Biopharma Company to Purchase a MiQLab System
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the MiQLab® System for automated, genetic testing, is pleased to announce that it has received...
Sep 01, 2022 08:00 am ET
LexaGene Announces MiQLab® System Sale to Veterinary Hospital in California
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the MiQLab® System for automated, genetic testing, is pleased to announce that it has entered...
Aug 29, 2022 08:00 am ET
LexaGene Verifies CDC Monkeypox Assay Works on MiQLab System and Readies Company Should an EUA be Declared
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the MiQLab® System for automated, genetic testing, announces the System can perform the Centers...
Aug 24, 2022 08:00 am ET
LexaGene’s MiQLab System Generates Leptospira Results in as Soon as 30 minutes using Isothermal Chemistry
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the MiQLab® System for automated, genetic syndromic testing for veterinarians, announces it has...
Aug 17, 2022 08:00 am ET
University of Pennsylvania’s School of Veterinary Medicine to Evaluate New Gastrointestinal Panel Using LexaGene’s MiQLab System
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the MiQLab® System for automated, genetic syndromic testing for veterinarians, announces the...
Aug 10, 2022 08:00 am ET
LexaGene Reduces Time-to-Result by ~35%
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the MiQLab® System for automated PCR-based syndromic testing in veterinary clinics, announces it has...
Jul 29, 2022 07:58 am ET
LexaGene Announces Filing of Financial Statements, Revocation of MCTO & the Granting of Incentive Equity Awards to Employees
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the MiQLab® System for automated PCR-based syndromic testing in veterinary clinics, is pleased to announce...
Jul 27, 2022 07:58 am ET
LexaGene Completes Multi-Center Validation Study Using MiQLab® System for Diagnosing Urinary Tract Infections
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the MiQLab® System for automated PCR-based syndromic testing in veterinary clinics, provides a brief summary...
Jul 12, 2022 08:00 am ET
LexaGene Provides MCTO Update
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the MiQLab® System for automated PCR-based syndromic testing in veterinary clinics, provides an update...
Jul 05, 2022 07:55 am ET
LexaGene Announces Webinar by UC Davis Professor on Use of MiQLab® System for Diagnosis of Urinary Tract Infections
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the MiQLab System for automated, multiplexing PCR-based syndromic testing in veterinary clinics, is pleased...
Jul 01, 2022 07:45 am ET
LexaGene Announces MiQLab® System Sale to Veterinary Hospital in Wisconsin
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the MiQLab® System for automated, multiplexing PCR-based syndromic testing in veterinary clinics, is pleased...
Jun 30, 2022 05:32 pm ET
LexaGene Announces Management Cease Trade Order
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”) announces, further to its news release on June 28, 2022, the Company has been granted a management cease trade order (“MCTO”) under National Policy 12-203 –...
Jun 28, 2022 06:46 pm ET
LexaGene Files Form 10 Registration Statement with the SEC and Announces a Delay in Filing Year-End Annual Canadian Financial Filings
LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”) announces that it has filed an initial registration statement with the United States Securities and Exchange Commission (the “SEC”) on Form 10 under the United States...
May 25, 2022 07:45 am ET
LexaGene Announces Multi-System Purchase from a Large Market Leader in Animal Health
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing, is pleased to announce a large veterinary animal health...
May 03, 2022 08:00 am ET
LexaGene Successfully Completes CRADA with US Army
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the MiQLab® System, a fully automated rapid pathogen testing device, today announced that the U.S. Army...
Apr 25, 2022 08:45 am ET
LexaGene Announces Multi-System Purchase from a Corporate Veterinary Reference Laboratory
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing, is pleased to announce a corporate veterinary reference...
Mar 29, 2022 07:45 am ET
LexaGene Announces Advancements to its Sample Preparation Cartridge for the Veterinary Market
LexaGene Holdings Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that has commercialized the MiQLab® System, a fully automated rapid pathogen testing device, today announced advancements to its sample preparation...
Feb 18, 2022 12:25 pm ET
LexaGene Announces Closing of Second Tranche of Investment by Strategic Institutional Investor
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing, is pleased to announce that it has closed the second...
Feb 08, 2022 08:20 am ET
LexaGene Announces $6.4 Million Investment by Strategic Institutional Investor
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing, is pleased to announce that Meridian LGH Holdings LLC,...
Jan 03, 2022 07:45 am ET
LexaGene Starts the Year with Additional MiQLab Sales
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing, is pleased to announce three additional purchase orders for MiQLab™...
Dec 17, 2021 01:08 pm ET
LexaGene Announces Results of Annual General and Special Meeting
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing, is pleased to announce the voting results of the Company’s 2021 Annual...
Dec 03, 2021 07:45 am ET
LexaGene Closes Multiple MiQLab Sales
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce two purchase orders from Kuma Veterinary Clinic and the...
Nov 24, 2021 04:00 pm ET
LexaGene Intends to Pursue Full Panel Pathogen Testing through the FDA
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing, today announced it intends to pursue both 510k clearance...
Nov 15, 2021 07:45 am ET
Leading Veterinary Academic, Dr. Jane Sykes, Joins LexaGene Board of Directors
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing, today announced Dr. Jane Sykes, BVSc(Hons), PhD, MBA,...
Nov 09, 2021 07:45 am ET
LexaGene Expands Bio-Pharma Contamination Panel by Adding Test that includes a Biothreat Agent
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing, today announced it has successfully expanded its bio-pharmaceutical...
Nov 02, 2021 07:45 am ET
LexaGene Receives 2021 BioTech Breakthrough Award
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing for veterinary diagnostics, today announced it was named...
Nov 01, 2021 07:45 am ET
LexaGene Finalizes Design of Pneumonia Panel
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing for veterinary diagnostics, today announced it has...
Oct 29, 2021 07:45 am ET
LexaGene Completes First Stage of U.S. ARMY DEVCOM Agreement
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing, today announced it has successfully detected anthrax...
Oct 27, 2021 07:45 am ET
LexaGene’s MiQLab™ System Selected to be a Best in Show Spotlight at the 47th Annual Industry Petcare Innovation Summit
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing for veterinary diagnostics, today announced it has been...
Oct 26, 2021 10:55 am ET
LexaGene to Host Corporate Update on November 3
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing for veterinary diagnostics and biopharmaceutical...
Oct 25, 2021 07:45 am ET
LexaGene Completes Analytical Studies for FDA EUA of COVID-19 Testing
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing for veterinary diagnostics and biopharmaceutical...
Oct 07, 2021 07:45 am ET
LexaGene’s Largest Study Validates Accuracy of its Veterinary Test Panel
Technology Accurately Identifies Pathogens and Predicts Antimicrobial Resistance In less than 30 years, drug resistant bacteria are predicted to kill 3 times more people on an annual basis than COVID-19 did in 2020MiQLab is a diagnostic tool...
Oct 06, 2021 08:32 am ET
LexaGene to Webcast Live at VirtualInvestorConferences.com October 7th
BEVERLY, Mass., Oct. 6, 2021 /PRNewswire/ -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) ("LexaGene" or the "Company"), a commercial molecular diagnostics company selling a point-of-need highly multiplexed in-clinic PCR system with results in approximately two hours, today announced Dr. Jack Regan, CEO and Founder, will present live at VirtualInvestorConferences.com on October 7th.
Oct 01, 2021 07:45 am ET
LexaGene Expands Brand Awareness at Key Investor Conferences
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a commercial molecular diagnostics company selling a point-of-need highly multiplexed in-clinic PCR system with results in approximately two hours, today announced...
Sep 30, 2021 08:27 am ET
Live Investor Conference & Webinar: Small Cap Growth Conference on October 7th
NEW YORK, Sept. 30, 2021 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Small Cap Growth Virtual Investor Conference. Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 8:45 AM ET on Thursday, October 7th with the first live webcast at 9:00 AM ET.
Sep 30, 2021 07:45 am ET
LexaGene Reports on Recent Veterinary Trade Shows
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a commercial molecular diagnostics company selling a point-of-need highly multiplexed in-clinic PCR system with results in approximately two hours, today provided an...
Sep 17, 2021 04:00 pm ET
LexaGene Adopts Corporate Governance Charters and Policies
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a commercial molecular diagnostics company selling a point-of-need highly multiplexed in-clinic PCR system with results in approximately two hours, today announced...
Sep 16, 2021 07:45 am ET
LexaGene Enters into Cooperative Research and Development Agreement with the United States Army’s Combat Capabilities Development Command
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce it has entered into a Cooperative Research and Development...
Sep 07, 2021 07:45 am ET
LexaGene’s MiQLab™ Accurately Detects Multiple Strains of Pathogenic Bacteria in Polymicrobial Samples Compared to Conventional Culture
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced it successfully utilized its MiQLab™...
Sep 03, 2021 03:15 pm ET
Lexagene Files Preliminary Short Form Base Shelf Prospectus
LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announces that it has filed and received a receipt for a preliminary short form...
Sep 03, 2021 07:45 am ET
LexaGene’s MiQLab™ System Featured at Three Key Veterinary Tradeshows
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) a molecular diagnostics company developing automated rapid polymerase chain reaction (PCR) testing solutions for veterinary diagnostics and biopharmaceutical manufacturing, is pleased to announce...
Aug 12, 2021 07:45 am ET
LexaGene Demonstrates a Simple and Inexpensive Multiplex PCR Chemistry with Shorter Lead Times for use on its MiQLab System
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) a molecular diagnostics company developing automated rapid polymerase chain reaction (PCR) testing solutions for veterinary diagnostics and biopharmaceutical manufacturing, is pleased to announce...
Jul 20, 2021 07:45 am ET
LexaGene’s MiQLab Detects Common Bioreactor Contaminant up to 300 Times Faster than Conventional Methods
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced it has successfully utilized its MiQLab™...
Jul 14, 2021 07:45 am ET
LexaGene Retains Wolf Greenfield Intellectual Property Law Firm
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a molecular diagnostics company that develops a fully automated rapid pathogen detection system, today announced its strategic relationship with Wolf Greenfield, an intellectual...
Jul 07, 2021 07:45 am ET
LexaGene Launches 2nd Generation Bacterial and Drug Resistance Test to Better Meet the Diagnostic Needs of Veterinarians
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced the release of its second-generation MiQLab™ Bacterial and AMR...
Jul 02, 2021 07:45 am ET
LexaGene Advances Towards FDA Emergency Use Authorization
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced it continues to systematically advance the MiQLab™ System to meet...
Jun 29, 2021 10:01 am ET
LexaGene Announces Fourth Quarter and Full-Year End February 28, 2021, Financial Results
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced that the Company filed their Annual Information Form and its...
Jun 28, 2021 07:45 am ET
LexaGene Engages LaVoieHealthScience as Integrated Investor and Public Relations Agency of Record
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG), (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce it has retained LaVoieHealthScience (LHS) as its investor...
Jun 24, 2021 07:45 am ET
New Sale of LexaGene’s MiQLab™ System Propels Early Diagnostic Testing in Veterinarian Practices
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced Meridian Veterinary Capital, LLC (“Meridian”) has purchased a MiQLab System to be...
Jun 17, 2021 07:45 am ET
LexaGene’s MiQLab Offers Rapid Plague Detection for Bioterrorism Threats
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) a molecular diagnostics company, is pleased to announce that today, Dr. Jack Regan, CEO and Founder of LexaGene, will present at the Biothreat and Pathogen Detection Conference regarding the...
Jun 14, 2021 07:45 am ET
LexaGene Closes Sale to Alpine Veterinary Hospital
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG), a molecular diagnostics company, announced the Company has sold another MiQLab™ System and the CEO will present at multiple conferences. LexaGene CEO and Founder, Dr. Jack Regan, states,...
Jun 10, 2021 07:45 am ET
LexaGene detects a slow-growing bacterium at least 36-times faster than conventional methods with the potential to increase vaccine safety and supply
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) a molecular diagnostics company that develops fully automated, rapid pathogen detection systems, today announced it has successfully utilized the MiQLab™ System to detect the presence of a slow...
Jun 07, 2021 07:45 am ET
LexaGene Sells a MiQLab System to Denver Animal Emergency
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce Denver Animal Emergency has provided LexaGene a purchase...
Jun 03, 2021 07:45 am ET
LexaGene Partners with Ethos Discovery to Develop New Companion Animal Diagnostic Tests
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce it has partnered with Ethos Discovery to expand the test...
Jun 01, 2021 07:45 am ET
LexaGene Takes Steps to List on the Nasdaq
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce it is taking steps to list its common shares on the Nasdaq...
May 11, 2021 07:45 am ET
LexaGene Expands its Sales Team
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce the hiring of four additional sales representatives,...
Apr 14, 2021 07:50 am ET
LexaGene Hosts a Seminar to Present MiQLab Data from Veterinary Samples
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to host a private event for a select group of veterinarians that will...
Apr 01, 2021 07:50 am ET
LexaGene’s Provides Corporate Update
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to provide a corporate update from LexaGene’s CEO and Founder Dr. Jack...
Mar 02, 2021 07:45 am ET
LexaGene Receives $3.6M from the Exercise of Warrants
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, announced today that the Company has received approximately $3.6M CAD ($2.9M USD)...
Feb 12, 2021 07:56 am ET
LexaGene Announces Change in Management and Appoints New Member to the Board of Directors
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, announces that Mr. Daryl Rebeck will resign from the Board and his position as the...
Feb 10, 2021 08:24 am ET
LexaGene’s MiQLab Successfully Detects Mutant UK and South African COVID-19 Sequences
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce that it has successfully configured a MiQLab™ system to...
Jan 13, 2021 08:43 am ET
LexaGene Initiates Program to Identify UK and South African COVID Sequences
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce that it has initiated a program that uses the rapid...
Jan 06, 2021 07:58 am ET
LexaGene to Present at Upcoming SNN Network and H.C. Wainwright Bioconnect 2021 Virtual Events
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce that it will be presenting at two upcoming investor...
Dec 30, 2020 07:58 am ET
LexaGene Starts FDA EUA Study for Point-of-Care COVID-19 Testing
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce that it has started a series of studies required by the FDA...
Dec 17, 2020 07:58 am ET
LexaGene to Place MiQLab Systems at Two Leading Specialty and Emergency Veterinary Care Hospitals
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce that it will place MiQLab™ systems into the busy clinical...
Dec 15, 2020 07:58 am ET
LexaGene Receives Purchase Order for MiQLab from Ethos Discovery
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce it has received a purchase order for a MiQLab™ system from...
Dec 09, 2020 07:58 am ET
LexaGene to Participate at the 13th Annual LD Micro Main Event Conference
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce that Dr. Jack Regan, LexaGene’s CEO and Founder, will...
Nov 18, 2020 07:58 am ET
LexaGene Places MiQLab System at the University of Pennsylvania’s School of Veterinary Medicine
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce that it has placed a MiQLab™ system into the clinical...
Nov 16, 2020 07:58 am ET
LexaGene Receives Purchase Order from a Multinational Biotechnology Company
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce that it has received a purchase order for a MiQLab™ system...
Nov 13, 2020 05:00 pm ET
LexaGene Announces Results of Annual General Shareholder’s Meeting
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce the voting results of the Company’s 2020 Annual General...
Nov 10, 2020 07:58 am ET
LexaGene to Present at Two Upcoming Investor Conferences
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce that the Company’s CEO and Founder Dr. Jack Regan will be...
Oct 05, 2020 09:01 am ET
LexaGene Provides a Corporate Update
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to provide a general corporate update. LexaGene aims to become the...
Sep 21, 2020 07:58 am ET
LexaGene’s CEO Provides Video Message on Company’s Progress and Announces Appointment of Dr. Shelley Rankin to Company’s Scientific Advisory Board
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to provide a video message from Dr. Jack Regan, LexaGene’s Founder and...
Sep 18, 2020 05:00 pm ET
LexaGene Engages Tailwinds Research Group
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce it has engaged Tailwinds Research Group to provide digital...
Sep 09, 2020 09:43 am ET
LexaGene Holdings Announces Closing of CAD$13.29 Million Financing
LexaGene Holdings Inc. (TSX VENTURE: LXG) (OTCQB: LXXGF) ("LexaGene" or the "Company") is pleased to announce that it has closed its previously announced offering of units (the “Units”) for aggregate gross proceeds of approximately CAD$13.29...
Aug 19, 2020 11:46 am ET
IIROC Trading Resumption - LXG
VANCOUVER, BC, Aug. 19, 2020 /CNW/ - Trading resumes in:
Aug 19, 2020 10:56 am ET
LexaGene Announces an Increase to Previously Announced Bought Deal Public Offering
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES./
Aug 19, 2020 09:03 am ET
IIROC Trading Halt - LXG
VANCOUVER, BC, Aug. 19, 2020 /CNW/ - The following issues have been halted by IIROC:
Aug 18, 2020 05:11 pm ET
LexaGene Announces $7.5 Million Bought Deal Public Offering
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES./
Aug 17, 2020 07:58 am ET
LexaGene Engages Contract Manufacturer to Support Product Launch
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce it has engaged LaunchWorks to support the commercial launch...
Jul 22, 2020 08:30 am ET
Testing’s Critical Role in Stemming the Tide
via NetworkWire — LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 40+ brands in the InvestorBrandNetwork (“IBN”), a multifaceted financial news and...
Jul 14, 2020 07:58 am ET
LexaGene Hires First Direct Sales Executives and announces exercise of warrants
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops genetic analyzers for rapid pathogen detection, is pleased to announce the hiring of its first wave of salespeople to support the...
Jul 13, 2020 07:58 am ET
LexaGene Introduces its Commercial Product MiQLab™
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops genetic analyzers for rapid pathogen detection, is pleased to announce the name and first look of the Company’s flagship product,...
Jul 08, 2020 07:58 am ET
LexaGene to Host Webcast on July 14, 2020
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops genetic analyzers for rapid pathogen detection, is pleased to announce that it will host a webcast investor presentation on Tuesday,...
Jun 22, 2020 08:50 am ET
LexaGene to Present at Lytham Partners Virtual Investor Growth Conference
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection, is scheduled to participate in a virtual presentation and fireside chat at the Lytham...
Jun 18, 2020 07:58 am ET
LexaGene Provides Status Update on COVID-19 Testing at a Major Hospital Laboratory
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, is pleased to provide a status update on the previously announced...
Jun 11, 2020 09:01 am ET
LexaGene Holdings, Inc. Discusses the Sales Strategy for Its Pathogen Detection Technology with the Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - June 11, 2020) - The Stock Day Podcast welcomed LexGene Holdings, Inc. (TSXV: LXG) (OTCQB: LXXGF) (the "Company"), a biotechnology company that develops genetic analyzers for rapid pathogen detection is pleased to provide the following update on the Company's development plans of its flagship pathogen detection platform for the human clinical, veterinary diagnostics, and food safety sectors. President of the Company, Daryl Rebeck, joined Stock Day host Everett Jolly.
Jun 03, 2020 08:00 am ET
The Global Race for Testing and Vaccines for COVID-19 Sees Biotechnology Innovation at its Best
Point Roberts, Washington and Delta, British Columbia--(Newsfile Corp. - June 3, 2020) - Investor Ideas, a global investor news source covering biotech and pharma stocks releases a COVID-19 sector snapshot. According to Bio.org, COVID-19 (Coronavirus) has ignited the sector, noting "Biotech Companies are responding faster than ever to emerging health threats." Investor ideas looks at some of the leading innovators and what is in the pipeline.
Jun 01, 2020 08:49 am ET
LexaGene Provides Update on Commercializing its Automated Pathogen Detection System
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”) a biotechnology company that develops genetic analyzers for rapid pathogen detection is pleased to provide the following update on the Company’s development plans of its flagship...
May 28, 2020 07:55 am ET
LexaGene Places a Pre-Commercial Instrument for COVID-19 Testing in a Major Hospital Laboratory
LexaGene Holdings, Inc. (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, is pleased to announce the placing of a pre-commercial instrument...
May 08, 2020 10:36 pm ET
LexaGene Holdings Receives Approval to Amend Warrant Terms
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”) announces that further to its April 29, 2020 press release, it has received approval from the TSX Venture Exchange to amend the exercise price of the common share purchase warrants...
Apr 23, 2020 05:00 pm ET
LexaGene Holdings Proposes to Amend Warrants Terms and Announces a Strategic Marketing Promotional Campaign
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”) announces that it intends to amend the exercise price of the common share purchase warrants (the “Warrants”) issued on March 29, 2019. In connection with a $2.65 million offering...
Apr 16, 2020 09:00 am ET
LexaGene CEO Discusses COVID-19 Testing, Commercialization Strategy -- SECFilings.com
Redondo Beach, California--(Newsfile Corp. - April 16, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an interview with Dr. Jack Regan, CEO and Founder of LexaGene Holdings Inc. (OTCQB: LXXGF) (TSX-V: LXG), discussing the company's development of genetic analyzers capable of quickly and accurately detecting pathogens, including COVID-19.
Apr 16, 2020 07:58 am ET
LexaGene Files Patent Application for Expanded Capabilities of Their LX Analyzer
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today the filing of a provisional patent application to...
Apr 01, 2020 07:58 am ET
LexaGene Appoints Dr. Eleanor Kolossovski to Director of Product Marketing
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, today announced the appointment of Dr. Eleanor Kolossovski to the...
Mar 24, 2020 07:58 am ET
LexaGene Appoints Steven Armstrong to Senior Director of Operations
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, today announced the appointment of Mr. Steven Armstrong to the...
Mar 17, 2020 03:08 pm ET
LexaGene Provides Update on the Exercise of Warrants
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, today announces that it has received proceeds from the exercise...
Mar 11, 2020 07:58 am ET
LexaGene Provides Corporate Update
LexaGene Holdings, Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, provides the following corporate update on the development of its...
Mar 09, 2020 07:00 am ET
Coronavirus Highlights Need for Rapid Testing of Pathogens -- SECFilings.com
Seattle, Washington--(Newsfile Corp. - March 9, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article discussing how LexaGene Holdings Inc. (OTCQB: LXXGF) (TSXV: LXG) is focused on making testing for pathogens quicker and easier than ever before.
Feb 20, 2020 07:58 am ET
LexaGene’s LX Analyzer Successfully Detects Coronavirus RNA using the CDC’s Tests
LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today the successful adaptation of the Centers...
Jan 27, 2020 07:58 am ET
LexaGene’s Analyzer is Designed to Detect Pathogens such as the Novel Coronavirus to Help Avert a Pandemic
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a biotechnology company that develops genetic analyzers for the rapid detection of pathogens and other molecular markers, has received many inquiries regarding the...
Jan 21, 2020 07:58 am ET
Newly-developed Tests Achieve 100% Concordance on Superbug Strains from the CDC
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today it has expanded its number of validated tests for...
Nov 13, 2019 07:58 am ET
LexaGene Provides Corporate Update
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, provides a corporate update. After reporting successful beta...
Oct 29, 2019 10:48 am ET
LexaGene Announces Closing of CAD$6.64 Million Financing
LexaGene Holdings Inc. (TSX VENTURE: LXG) (OTCQB: LXXGF) ("LexaGene" or the "Company") is pleased to announce that it has closed its previously announced offering of units (the “Units”) for aggregate gross proceeds of CAD$6.64 million (the...
Oct 22, 2019 02:25 pm ET
LexaGene Holdings Announces Filing of Final Prospectus
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Oct 02, 2019 07:40 am ET
LexaGene Holdings Announces Pricing of Prospectus Offering
LexaGene Holdings Inc. (TSX VENTURE: LXG) (OTCQB: LXXGF) ("LexaGene" or the "Company") is pleased to announce today the pricing of its marketed public offering, which was previously announced in a press release dated September 24, 2019 (the...
Sep 25, 2019 07:58 am ET
LexaGene Holdings Announces Proposed Offering of Units and Filing of Preliminary Prospectus
LexaGene Holdings Inc. (TSX VENTURE: LXG) (OTCQB: LXXGF) ("LexaGene" or the "Company") is pleased to announce that it has filed a preliminary short form prospectus (the “Prospectus”) with the securities regulatory authorities in each of the...
Sep 19, 2019 07:58 am ET
LexaGene Reports on Successful Results from Beta Testing in Human Clinical Diagnostics Laboratory
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today it has completed beta testing with Assurance...
Sep 17, 2019 07:58 am ET
LexaGene Develops Test for Deadly Mosquito-borne EEE Virus
LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers that can rapidly detect pathogens and other molecular markers, announced today the development of a test for detection of the...
Sep 12, 2019 07:58 am ET
LexaGene Announces its Second Hemp-Cannabis Reference Testing Laboratory as a Beta Test Site
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene”) or the (“Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today plans to place its LX Analyzer...
Sep 05, 2019 10:47 am ET
LexaGene Reports on Beta Results from Cannabis-Focused Testing Laboratory
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today that in August it placed a beta unit at CDX...
Aug 08, 2019 07:58 am ET
LexaGene to Place Beta Unit in Human Clinical Diagnostics Laboratory
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today it has an agreement to place a beta prototype...
Jul 30, 2019 08:00 am ET
LexaGene Approved by CDC and FDA Antibiotic Resistance Isolate Bank to Receive Samples to Test for Superbugs
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that it has been recognized by the Centers for Disease...
Jul 17, 2019 07:58 am ET
LexaGene Files Three Additional US Patents Covering Technology
LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that it has filed additional patents to protect the...
Jul 10, 2019 07:58 am ET
LexaGene’s Beta Prototype Exceeds Expectations During Testing at Massachusetts Veterinary Referral Hospital
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today the test results from its first beta prototype...
Jun 06, 2019 12:05 am ET
LexaGene Will Host a Free Webinar Providing an Overview of the Company
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announce that LexaGene will host a webinar today, Thursday, June...
Jun 05, 2019 07:58 am ET
LexaGene Places its First Beta Prototype into Massachusetts Veterinary Referral Hospital
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today that it has placed its first beta prototype into...
May 15, 2019 07:58 am ET
LexaGene Completes Development of Antibiotic Resistance Panel
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today that it has completed the development of an...
Apr 30, 2019 03:00 am ET
LexaGene’s Technology Successfully Detects a Common Fungus That Damages Agricultural Crops
LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that its LX analyzer successfully detects Botrytis...
Apr 24, 2019 09:00 am ET
Uptick Newswire Hosts LexaGene Holdings Inc. on The Stock Day Podcast to Discuss the Beta Launch of Their Pathogen Detection Device
PHOENIX, AZ / ACCESSWIRE / April 24, 2019 / Uptick Newswire Stock Day Podcast welcomed LexaGene (OTCQB: LXXGF) (TSXV: LXG) (''the Company''), a biotechnology company developing the very first fully automated pathogen detection platform that is open-access. President, Daryl Rebeck, joined Stock Day host Everett Jolly.
Apr 24, 2019 07:55 am ET
LexaGene’s Technology Identifies Genetic Mutations Directly from Cheek Swabs
LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that its LX technology can successfully detect...
Apr 16, 2019 08:00 am ET
LexaGene Engages Bristol Capital LTD. to Provide Investor Relations and Communications Services
LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that it has entered into a consulting agreement with...
Apr 03, 2019 03:01 am ET
Former Head of Food Safety at Chipotle Mexican Grills Joins LexaGene’s Scientific Advisory Board
LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, is pleased to announce that food safety innovator Dr. James Marsden has...
Mar 29, 2019 08:00 am ET
LexaGene’s Closes Oversubscribed Private Placement
LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, is pleased to announce it has closed an oversubscribed non-brokered...
Mar 13, 2019 12:05 am ET
LexaGene Announces C$1.95 Million Private Placement
LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that, subject to acceptance by the Exchange, it intends...
Mar 11, 2019 08:00 am ET
LexaGene’s CEO Invited by USDA to Present a Seminar on the Benefits of Adopting Rapid Genetic Testing to Improve Food Safety
LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that Dr. Jack Regan, LexaGene’s CEO and Founder, was...
Mar 05, 2019 03:04 am ET
LexaGene’s LX Technology Successfully Detects Pathogenic E. coli O157:H7 Bacteria from Romaine Lettuce Wash
LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that their LX technology successfully detected E. coli...
Feb 25, 2019 03:04 am ET
LexaGene Completes Pilot Clinical Study and Reports Results
LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that as part of the Company’s previously announced pilot...
Feb 12, 2019 03:04 am ET
LexaGene’s Technology Successfully Detects Antibiotic Resistance Factors
LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that its LX technology can detect the presence of...
Feb 07, 2019 04:04 pm ET
LexaGene’s Technology Successfully Detects Dual Infected Samples
LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that its LX technology has successfully detected the...
Feb 04, 2019 04:04 pm ET
LexaGene Starts Clinical Study Using its Technology
LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that it has started a clinical study to collect data...
Jan 22, 2019 07:04 pm ET
LexaGene Announces Formation of Scientific Advisory Board
LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that the Company has formed a scientific advisory board...
Jan 03, 2019 08:30 am ET
LexaGene Featured on ABC Affiliate WCVB-TV Boston
LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops instrumentation and assays for pathogen detection, today announced that the Company was featured on ABC-affiliated television station WCVB...
Dec 10, 2018 08:30 am ET
LexaGene Completes Development of Canine UTI Syndromic Panel
LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops instrumentation and assays for pathogen detection, today announced the completion of a syndromic panel to detect urinary tract infection (UTI)...
Dec 03, 2018 08:30 am ET
LexaGene Attends Industry Engagement Meeting with the Department of Homeland Security
LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, today announced that it recently had an Industry Engagement Meeting with the Department of Homeland...
Nov 28, 2018 09:39 am ET
LexaGene Named One of the 10 Most Promising Food Solution Providers
LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, today announced that following the most recent widespread multi-state recall of romaine lettuce...
Oct 22, 2018 04:00 pm ET
LX2 Prototype Model Unveiled at AAVLD
LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, announced today that we successfully unveiled our LX2™ beta prototype design on October 20th, 2018 to...
Oct 09, 2018 08:30 am ET
LexaGene To Unveil LX2™ Beta Prototype Design for the Veterinary Market
LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, announced today that it will unveil a model of its low-cost LX2™ Beta Prototype at the American...
Sep 04, 2018 08:30 am ET
LexaGene to Present at Two Upcoming Investor Conferences
LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, today announced that the Company’s President, Daryl Rebeck, will present at two upcoming investor...
Jul 26, 2018 08:00 am ET
LexaGene Begins Beta Development of Pathogen Detection System
LexaGene Holdings Inc. (OTCQB:LXXGF) (TSX-V:LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, today announced that it has entered into the beta stage of product development of its flagship pathogen...
Jul 11, 2018 09:24 am ET
LexaGene Holdings Inc. Completes $5.75 Million Bought Deal Financing Underwriters Exercise Over-Allotment Option in Full
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Jun 19, 2018 04:58 pm ET
LexaGene Holdings Inc. Announces C$5.0 Million Bought Deal
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Jun 18, 2018 08:00 am ET
LexaGene Names Medical Device Veteran Joseph Caruso to Board of Directors
LexaGene Holdings Inc. (OTCQB:LXXGF) (TSX-V:LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, today announced the appointment of Joseph Caruso, to the Company’s Board of Directors. “Mr. Caruso is...
Jun 06, 2018 08:00 am ET
LexaGene Announces Collaboration with Texas A&M Veterinary Medical Diagnostics Laboratory
LexaGene Holdings Inc. (OTCQB:LXXGF) (TSX-V:LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, announced today that it has entered into a collaborative agreement with Texas A Veterinary Medical...
May 29, 2018 09:16 am ET
LexaGene Enters Collaboration to Incorporate Cancer Sequencing Technology into a New Product
LexaGene Holdings Inc. (OTCQB:LXXGF) (TSX-V:LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, announced today that it has entered into an agreement with the Stanford University School of Medicine....
May 15, 2018 11:27 am ET
LexaGene’s Prototype for Better Pathogen Detection Now Capable of Identifying E. coli and Staph
With the recent outbreaks associated with romaine lettuce (E. coli) and eggs (Salmonella) in the headlines, LexaGene Holdings Inc. (OTCQB:LXXGF (TSXV:LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen...
Apr 04, 2018 09:54 am ET
LexaGene Announces Collaboration with Ethos Veterinary Health
BEVERLY, Mass., April 04, 2018 (GLOBE NEWSWIRE) -- LexaGene Holdings Inc. (OTCQB:LXXGF) (TSX-V:LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, announced today that it has entered into collaboration with Ethos Veterinary Health, a veterinary...
Mar 01, 2018 08:45 am ET
LexaGene Appoints New Chief Financial Officer
BEVERLY, Mass., March 01, 2018 (GLOBE NEWSWIRE) -- LexaGene Holdings Inc. (OTCQB:LXXGF) (TSX-V:LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, announces the appointment of Jeffrey Mitchell as Chief Financial Officer of the Company, who...
Feb 22, 2018 09:58 am ET
LexaGene Honored as a Top 50-Ranked TSX Venture Company
TSX Venture 50 Ranks the Strongest Companies on TSX Venture Exchange by Share Price, Trading Volume and Market Capitalization
Feb 21, 2018 12:26 pm ET
LexaGene Grants Compensation Awards
BEVERLY, Mass., Feb. 21, 2018 (GLOBE NEWSWIRE) -- LexaGene Holdings Inc. (OTCQB:LXXGF) (TSX-V:LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, announces that, pursuant to the Company’s Omnibus Incentive Plan, the Company granted on February...
Feb 13, 2018 08:45 am ET
LexaGene Appoints Nathan Walsh to Director of Applications – Bioinformatics and Manoj Nair to Senior Staff Scientist
New Executive Leaders, Experienced in DNA Sequencing Analysis and Scientific Innovation, Join Pathogen Detection Biotech Company
Feb 06, 2018 08:30 am ET
LexaGene Leases Larger Space to Support Company Growth
VANCOUVER, British Columbia, Feb. 06, 2018 (GLOBE NEWSWIRE) -- LexaGene Holdings Inc. (OTCQB:LXXGF) (TSX-V:LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, today announced that the Company has significantly expanded its operations in Massachusetts. LexaGene...
Jan 25, 2018 08:30 am ET
LexaGene Appoints Greg Dale to Vice President of Product Development and Manufacturing
Addition to Senior Leadership Brings Strong Tech Product Commercialization Experience to Pathogen Detection Biotech Company
Jan 22, 2018 12:25 pm ET
LexaGene Holdings Inc. Announces Closing of Over-Allotment Option
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Dec 19, 2017 10:47 am ET
LexaGene Holdings Inc. Announces Closing of C$5.0 Million Bought Deal Financing
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Dec 04, 2017 09:00 am ET
LexaGene Announces Refiling of Annual Information Form
VANCOUVER, British Columbia, Dec. 04, 2017 (GLOBE NEWSWIRE) -- LexaGene Holdings Inc. (OTCQB:LXXGF) (TSX-V:LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, announces that it has filed an amended annual information form for the year...
Nov 30, 2017 08:30 am ET
LexaGene Completes Prototype Assembly for Soon-To-Be First Fully Automated, Open-Access Pathogen Detection System
New Technology Will Revolutionize Pathogen Detection Across Food Safety, Veterinary and Human Clinical Diagnostics
Nov 29, 2017 11:14 am ET
IIROC Trade Resumption - Lexagene Holdings Inc.
Vancouver, British Columbia--(Newsfile Corp. - November 29, 2017) - Trading resumes in:
Nov 29, 2017 10:12 am ET
IIROC Trading Resumption - LXG
VANCOUVER, Nov. 29, 2017 /CNW/ - Trading resumes in:
Nov 28, 2017 03:52 pm ET
IIROC Trade Halt - Lexagene Holdings Inc.
Vancouver, British Columbia--(Newsfile Corp. - November 28, 2017) - The following issues have been halted by IIROC:
Nov 28, 2017 03:37 pm ET
LexaGene Holdings Inc. Announces C$5.0 Million Bought Deal
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Nov 28, 2017 02:55 pm ET
IIROC Trading Halt - LXG
VANCOUVER, Nov. 28, 2017 /CNW/ - The following issues have been halted by IIROC:
Oct 12, 2017 03:27 pm ET
LexaGene unaware of any material change
VANCOUVER, British Columbia, Oct. 12, 2017 (GLOBE NEWSWIRE) -- LexaGene Holdings Inc. (OTCQB:LXXGF) (TSX-V:LXG) (the “Company”), at the request of IIROC, LexaGene Holdings Inc. wishes to confirm that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity....
Mar 21, 2017 02:29 pm ET
LexaGene selected to be highlighted on FOX Business Network
VANCOUVER, British Columbia, March 21, 2017 (GLOBE NEWSWIRE) -- LexaGene Holdings Inc. (OTCQB:LXXGF) (TSX-V:LXG) (the “Company”). LexaGene is pleased to announce that DMG Productions has selected LexaGene to be featured in an upcoming episode of Innovations with Ed Begley Jr. The show will air in the third quarter of 2017 on the FOX Business Network, which is viewed by approximately 85 million households worldwide. As a benefit of being selected, DMG will also produce a 30-second educational commercial spot to air during prime-time on networks such as the Discovery Channel, Fox Business,...
Mar 13, 2017 06:37 pm ET
LexaGene closes non-brokered private placement
VANCOUVER, British Columbia, March 13, 2017 (GLOBE NEWSWIRE) -- LexaGene Holdings Inc. (TSX-V:LXG) (OTCQB:LXXGF) (the “Company”). LexaGene is pleased to announce that further to its news release of February 10, 2017 the Company closed its non-brokered private placement (the “Offering”) with the sale of 6,685,363 units at $0.30 per unit for gross proceeds of $2,005,609. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to acquire an additional common share for $0.60 per share for a three year period. The Company intends to use th...
Mar 09, 2017 06:14 pm ET
LexaGene started trading on the OTCQB Venture Market in the United States under the symbol LXXGF
VANCOUVER, British Columbia, March 09, 2017 (GLOBE NEWSWIRE) -- LexaGene Holdings Inc. (TSX-V:LXG) (the “Company”). LexaGene is pleased to announce that the Company has started trading on the OTCQB Venture Market in the United States under the symbol LXXGF. The OTCQB is equivalent in Canada to the TSX Venture Exchange for early-stage and developing companies....
Feb 14, 2017 09:00 am ET
LexaGene announces non-brokered private placement
LexaGene Holdings Inc. (TSX VENTURE: LXG) (the "Company"). LexaGene is pleased to announce it intends to complete a non-brokered private placement to raise up to $2,010,000 by the issuance of 6,700,000 units at $0.30 per unit. Each unit will consist...
Feb 07, 2017 04:03 pm ET
LexaGene Announces Website Launch
LexaGene Holdings Inc. (TSX VENTURE: LXG) (the "Company"). LexaGene is pleased to announce the launch of its new website www.lexagene.com. The website consolidates information already in the public domain. The Company would also like to announce...
Feb 03, 2017 09:00 am ET
LexaGene Announces Appointment of New President
LexaGene Holdings Inc. (TSX VENTURE: LXG) (the "Company"). LexaGene is pleased to announce the appointment of Mr. Daryl Rebeck as President of the Company. Mr. Rebeck is currently a director of LexaGene and has accepted this new position as...
Oct 18, 2016 05:12 pm ET
IIROC Trading Resumption - ZKL; LXG; TAC
VANCOUVER, Oct. 18, 2016 /CNW/ - Trading resumes in:
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
